structure glp 1 of Semaglutide-bound Glucagon-Like Peptide-1 Receptor (GLP-1R) in Complex with Gs Protein Schematic representation of different GLP-1

All opinions and descriptions are based on published research and publicly available information

Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile

Semaglutide Wegovy costs can vary based on insurance coverage and dose if paying cash

With minimal reported side effects , this formulation is well-tolerated and ideal for long-term use

doi: 10.1016/j.snr.2025.100281 34 LiuYZhangQDuJGuoR